Glaxosmithkline Pharmaceuticals DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	0.74×	0.74×	0.74×	0.72×	0.73×
	1.13×	1.13×	1.13×	0.97×	1.13×
	32.5%	32.5%	29.6%	24.3%	22.7%
	0.91×	0.91×	0.98×	1.00×	0.82×
	1.89×	1.89×	2.11×	2.00×	1.91×
	46.5%	46.7%	51.0%	34.2%	29.4%
	49.1%	49.1%	49.8%	33.5%	27.7%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

GLAXO₹2,515.10

Glaxosmithkline Pharmaceuticals Ltd.

· Pharma & Health

₹ CrorePeersPFIZER ABBOTINDIA MEDANTA ANTHEM AJANTPHARM IPCALAB GLENMARK BIOCONMcap ₹42,608 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.73	0.72	0.74	0.74	0.74
Interest Burden (Pretax/EBIT) ×	1.13	0.97	1.13	1.13	1.13
EBIT Margin %	22.71	24.29	29.62	32.52	32.54
Asset Turnover ×	0.82	1.00	0.98	0.91	0.91
Financial Leverage (Assets/Equity) ×	1.91	2.00	2.11	1.89	1.89
ROE (5-step product, year-end total equity) %	29.42	34.18	51.04	46.69	46.51
ROE (owners' profit / average owners' equity) %	27.73	33.53	49.75	49.11	49.11

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.